Clinica Chimica Acta最新文献

{"title":"Pulmonary nodules: A study on combined diagnostic methods and therapeutic evaluation","authors":"Lisha Wang ,&nbsp;Jingli Fan ,&nbsp;Siqi Wu ,&nbsp;Jiajia Liu ,&nbsp;Wenhao Wang","doi":"10.1016/j.cca.2025.120647","DOIUrl":"10.1016/j.cca.2025.120647","url":null,"abstract":"<div><div>Lung cancer remains a leading cause of cancer-related mortality globally, with pulmonary nodules critical for early detection and risk stratification. While low-dose spiral computed tomography (LDCT) has improved screening, its high sensitivity demands more accurate triage to reduce unnecessary invasive procedures. This study evaluated combining blood-based biomarkers—traditional tumor markers, cell-free DNA (cfDNA) methylation, and seven tumor-associated autoantibodies (7-AABs)—for identifying high-risk nodules and assessing treatment response. A total of 141 lung cancer patients with pulmonary nodules and 82 with benign nodules were enrolled. All underwent preoperative detection of traditional markers (CEA, VEGF, etc.), cfDNA methylation (SHOX2, RASSF1A, PTGER4), and 7-AABs (p53, SOX2, etc.). Lung cancer patients also had postoperative and post-chemotherapy assessments of cfDNA methylation and 7-AABs. Imaging features (size, morphology) were evaluated, with analyses including chi-square tests, logistic regression, and ROC curves. Results showed cfDNA methylation had the highest diagnostic efficacy (sensitivity: 78.0 %, specificity: 76.8 %, AUC: 0.7743), followed by 7-AABs (43.3 % sensitivity, 87.8 % specificity, AUC: 0.6553). Traditional markers were less useful (highest AUC: 0.5768 for SCC). Logistic regression identified high-risk morphology (OR = 2.676), positive cfDNA methylation (OR = 15.733), and positive 7-AABs (OR = 3.821) as independent malignancy predictors. Both biomarkers decreased postoperatively, with cfDNA methylation further declining after chemotherapy, suggesting utility for minimal residual disease monitoring. This study demonstrates combining imaging with cfDNA methylation and 7-AABs enhances preoperative risk stratification. These biomarkers also show promise for evaluating treatment response and guiding surveillance, supporting their use in precise lung cancer management.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120647"},"PeriodicalIF":2.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune diseases drive biological false-positive syphilis serology: A retrospective cohort of 35,995 tests","authors":"Bin Chen ,&nbsp;ZiJian Jiang ,&nbsp;MinHong Lyu","doi":"10.1016/j.cca.2025.120643","DOIUrl":"10.1016/j.cca.2025.120643","url":null,"abstract":"<div><h3>Objectives</h3><div>To analyze the related factors that may cause the biological false-positive (BFP) reaction of syphilis screening test, with a particular focus on the correlation between autoimmune diseases and the biological false-positive results of syphilis screening test. This study aims to provide insights into the mechanisms underlying BFP reactions in autoimmune diseases and to improve the accuracy of syphilis serological diagnosis.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review of 35,995 individuals who underwent syphilis screening at Guangzhou First People's Hospital from 2016 to 2023. The clinical characteristics including age, gender, and underlying diseases were compared between patients with BFP and those with a negative result of syphlilis screening test. The differences in autoantibody profiles and anticardiolipin antibody detection results of BFP patients and negative groups were analyzed.</div></div><div><h3>Results</h3><div>The observed incidence rate for biological false-positive reactions was 0.78 %, among which 96.7 % of cases exhibited relatively low titers (≤1:4). Significant differences in BFP responses were observed across different age groups (<em>P</em> &lt; 0.05). In the false positive group, the positive rates of anti-double-stranded DNA antibody (ds-DNA), anti-ribosomal antibody (rRNP), soluble substance A (SSA), anti-Sm antibody (Sm), anti-ribonucleoprotein antibody (nRNP), histone, anti-nucleosome antibody (AauA), centromere antibody (CENP B), and antinuclear antibody (ANA) were significantly higher compared to the negative group (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Autoimmune diseases and specific autoantibodies are key contributors to syphilis BFP reactions. Incorporating autoimmune testing may improve screening accuracy.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120643"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145263101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sepsis diagnosis and monitoring: Frontiers in innovative technology","authors":"Seyedeh Azin Mirmotahari ,&nbsp;Armin Salek maghsoudi ,&nbsp;Masoomeh Amini ,&nbsp;Mojdeh Safari ,&nbsp;Mohammad Akrami ,&nbsp;Seyed Iman Mirnezami ,&nbsp;Atabak Najafi ,&nbsp;Parisa Kianpour ,&nbsp;Mojtaba Mojtahedzadeh ,&nbsp;Shokoufeh Hassani","doi":"10.1016/j.cca.2025.120640","DOIUrl":"10.1016/j.cca.2025.120640","url":null,"abstract":"<div><div>One of the most common hospital-associated infections, especially in the ICU, is sepsis, and its early detection is a significant issue that health care systems must contend with. Effective treatment of sepsis requires early diagnosis and rapid therapeutic intervention. The early detection of this life-threatening condition is significantly improved not only by identifying drug-resistant pathogens but also by detecting unique immune response biomarkers that arise upon pathogen invasion, thus creating a critical early warning system. The methodology involves advanced molecular diagnostic tools, such as real-time PCR, MALDI-TOF mass spectrometry, and novel biomarker detection platforms. These methods enable faster identification of pathogens and biomarkers, enhancing the accuracy and speed of sepsis diagnosis. We also discuss the integration of these technologies with clinical workflows, considering their impact on patient outcomes and healthcare efficiency. In this paper, we review novel and rapid sepsis diagnostic techniques compared to traditional methods, emphasizing the significance and efficiency of the emerging technologies. An extensive review of the literature was conducted through databases such as PubMed, Scopus, Web of Science, and Google Scholar with keywords such as “sepsis” and “diagnostic strategies” to identify the most suitable articles for this review. Effective management of sepsis, a complex and deadly disease, relies on knowledge and application of rapid diagnostic techniques, such as new analytic tools, for successful treatment and improved patient outcomes. Advanced molecular diagnosis and clinical trials are maximizing therapeutic control with biomarker tracking (sTREM-1, IL-6, PCT) and improving diagnostic accuracy. Introducing new technologies in molecular diagnosis, analysis, and clinical management is crucial to improve septic shock patient outcomes. Our review highlights that while traditional methods such as blood culture remain essential, they are limited by long turnaround times and reduced sensitivity. Rapid molecular assays (PCR, MALDI-TOF) and biosensor-based point-of-care platforms provide results within hours, enabling earlier targeted treatment. Among biomarkers, procalcitonin remains the most established, but newer candidates such as presepsin, CXCL5, and circRNAs show promising diagnostic and prognostic potential. Integrating these innovative technologies into clinical workflows can enhance early detection, support antimicrobial stewardship, and ultimately improve patient survival.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120640"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoassay-based biomarkers in atopic dermatitis","authors":"Khalid Orayj ,&nbsp;Vijaya Paul Samuel ,&nbsp;Shakir Saleem ,&nbsp;Sahithya Ravali Ravula ,&nbsp;Haider Ali ,&nbsp;Gaurav Gupta ,&nbsp;K. Benod Kumar ,&nbsp;Pran Kishore Deb ,&nbsp;Kumarappan Chidambaram","doi":"10.1016/j.cca.2025.120634","DOIUrl":"10.1016/j.cca.2025.120634","url":null,"abstract":"<div><div>Atopic dermatitis (AD) is a persistent and recurring inflammatory skin condition that affects 204 million people worldwide, with prevalence rates of 11.1 % among children and 6.3 % among adults. This condition affects multiple systems, resulting in pruritus, skin barrier defects, and a Th2-driven immune imbalance, which consequently leads to significant costs and a diminished quality of life. To enhance precision medicine in laboratory diagnostics, it is essential to identify a neutral biomarker that can complement traditional severity assessments, such as SCORAD and EASI, for the diverse phenotypes and endotypes of AD. This narrative review examines immunoassay-based biomarkers with proven clinical validity in diagnostic laboratory medicine. Biomarkers such as TARC/CCL17, IL-13, IL-22, IL-31, SCCA1/SCCA2, and periostin are assessed using various tests, including ELISA, bead-based multiplexing, proximity extension, and highly sensitive digital methods. The samples included serum, plasma, and skin samples obtained through tape-stripping and microneedle collection. The parameters for analytical validation included detection and quantification limits, reportable range, precision, linearity, carryover effects, method comparison, interference assessment, heterophile antibody effects, calibration, and external quality standards. Clinical performance assessment uses measures such as the area under the curve (AUC), likelihood ratios, and decision limitations. Conventional biomarkers, including total IgE, peripheral eosinophil count, and tryptase, show less clinical utility than new biomarkers. Critical implementation requirements include standardized skin sample collection methods, population-specific reference intervals, inter-platform harmonization, and consensus-based cut-off values with clinical significance. This review outlines an evidence-based plan for incorporating reliable AD biomarker tests into current diagnostic methods to facilitate precise skin treatment and personalized care.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120634"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From objective grouping to fuzzy reference intervals: A standardized machine learning approach for thyroid function tests","authors":"Semih Fazlı Kayahan ,&nbsp;Muhammed Fatih Alaeddinoğlu ,&nbsp;Mehmet Şeneş","doi":"10.1016/j.cca.2025.120635","DOIUrl":"10.1016/j.cca.2025.120635","url":null,"abstract":"<div><h3>Background</h3><div>Accurate interpretation of thyroid function tests (TFTs) requires reliable reference intervals (RIs). Indirect methods based on retrospective laboratory data are increasingly used, but current strategies face major limitations, including rigid age cut-offs, inconsistent partitioning, and lack of objective evaluation of subgrouping criteria. To address these challenges, we developed a novel machine learning (ML)-based framework for the objective, data-driven determination of continuous and personalized RIs.</div></div><div><h3>Methods</h3><div>A total of 48,397 records (2019–2021) from individuals aged ≥18 years were retrieved from the hospital laboratory information system. After applying inclusion and exclusion criteria, 9455 individuals constituted the reference sample group. Partitioning was based on age, sex, thyroid-stimulating hormone (TSH), and free thyroxine (fT4). The Elbow method suggested the optimal number of clusters; K-means clustering was used to form subgroups, and the Extra Trees Classifier quantified the relative importance of partitioning criteria. RIs were estimated using the non-parametric percentile method, and Fuzzy C-Means clustering was applied to smooth sharp transitions between groups.</div></div><div><h3>Results</h3><div>Six subgroups were identified, with age as the dominant determinant (feature importance score = 0.96), whereas sex had a negligible effect. Fuzzy clustering generated continuous and personalized RIs. In clinical evaluation, applying fuzzy RIs reclassified 7 % of patients, predominantly shifting diagnoses toward hyperthyroidism.</div></div><div><h3>Conclusions</h3><div>This study offers a universal and adaptable ML-based framework for generating continuous, personalized RIs. This advance toward precision laboratory medicine can enhance diagnostic accuracy, reduce misclassification, and support more patient-centered care.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120635"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive increase of serum zinc level in a Pediatric patient with PSTPIP1- p.N236K mutation","authors":"Cyrus Takahashi ,&nbsp;Devon Rotramel ,&nbsp;Rejwi A. Dahal ,&nbsp;Amani Dickenson ,&nbsp;John O. Ogunbileje","doi":"10.1016/j.cca.2025.120646","DOIUrl":"10.1016/j.cca.2025.120646","url":null,"abstract":"<div><h3>Background</h3><div>Mutations of the cytoskeletal protein proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1) are associated with a spectrum of rare autoinflammatory disorders, including PAPA (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) and PAMI (PSTPIP1-associated myeloid-related inflammatory) syndromes, characterized by various dermatologic and hematologic abnormalities. Mechanistically, this has been linked to an increased affinity for pyrin, leading to autoinflammation and caspase-1 activation. We present a case report of a rare missense PSTPIP1 variant not previously associated with clinically significant findings.</div></div><div><h3>Case Report and Results</h3><div>The patient is a full-term Caucasian male who presented shortly after birth with pancytopenia in the setting of presumed bacterial meningitis. Whole genome sequencing identified a c.708C &gt; G, p.N236K missense mutation in PSTPIP1, which is not present in the population database gnomAD. A similar c.708C &gt; A, p.N236K variant is classified as being of uncertain significance on ClinVar (Variation ID: 1022810) based on a single submission, but is not currently linked to PAMI syndrome. This patient further demonstrated a progressive increase in serum zinc concentrations and autoinflammation markers.</div></div><div><h3>Conclusion</h3><div>This case report provides support for other pathogenic PSTPIP1 mutations associated with PAMI syndrome with a progressive increase in zinc and autoinflammation biomarkers. Furthermore, it addresses difficulties in establishing the diagnosis. It emphasizes the utility of molecular testing when faced with inexplicable clinical presentations and the need for an integrated diagnostic algorithm for PAMI.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120646"},"PeriodicalIF":2.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145263067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer diagnostics: non-coding RNAs and biosensors to AI-derived methods","authors":"Seyyed Navid Mousavinejad ,&nbsp;Rania Lachouri ,&nbsp;Felora Ferdosi ,&nbsp;Seyyed Hossein Khatami","doi":"10.1016/j.cca.2025.120641","DOIUrl":"10.1016/j.cca.2025.120641","url":null,"abstract":"<div><div>Cervical cancer ranks fourth in terms of cancer mortality among women. The most important risk factor for cervical cancer is infection with HPV 16 and HPV 18. The prevalence and mortality rates of this cancer are much higher in countries with low and medium development indices than in developed countries. Improving health, access to vaccination, and screening tests are highly helpful in preventing this type of cancer. Recent advances have revealed novel biomarkers, particularly noncoding RNAs, including microRNAs, long noncoding RNAs, and circular RNAs, which are promising biomarkers for early detection and disease monitoring. Concurrently, artificial intelligence (AI)-derived methods, which leverage machine learning and deep learning algorithms, have revolutionized diagnostic accuracy by enhancing image analysis and pattern recognition in cytology and histopathology. This review focused on the latest developments in cervical cancer diagnostic technologies, with a focus on the role of noncoding RNAs, biosensors, and AI-derived methods (machine learning and deep learning approaches) in clinical diagnosis. By evaluating the strengths, challenges, and future potential of these innovations, we aim to provide a deeper understanding of noncoding RNAs and AI-derived methods as a future for the laboratory diagnosis of cervical cancer.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120641"},"PeriodicalIF":2.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145263064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laboratory diagnostic in multiple myeloma: Quantification of daratumumab blood levels using isoelectric focusing.","authors":"Rieke Reiter, Christoph Mann, Wolfgang Andreas Nockher","doi":"10.1016/j.cca.2025.120650","DOIUrl":"https://doi.org/10.1016/j.cca.2025.120650","url":null,"abstract":"<p><strong>Objectives: </strong>Therapeutic monoclonal antibodies (tmAbs) such as daratumumab (DmAb) are among the primary treatment options for multiple myeloma. The availability of immunoassays for measuring tmAb blood levels is limited, although determining antibody concentrations may be of interest in cases of unexpected clinical outcomes. As has previously been demonstrated, isoelectric focusing (IEF) can be used to identify tmAbs and their differentiation from paraproteins. Here, the use of IEF for measuring tmAb concentrations is further expanded.</p><p><strong>Methods: </strong>First, a DmAb standard series ranging from 2.5 to 0.08 mg/L spiked with a polyclonal IgG background of 2.5 mg/L was defined and evaluated. After establishing the standard series, the DmAb concentrations were analyzed in patient blood samples collected one to five weeks post-administration, depending on the time after administration and the corresponding therapy phase.</p><p><strong>Results: </strong>DmAb concentrations stabilized three to four weeks after administration. Within a therapy cycle, profound differences in DmAb levels were observed when comparing the induction, consolidation and maintenance phase.</p><p><strong>Conclusion: </strong>IEF is a suitable tool for evaluating blood concentrations of DmAb and possibly other tmAbs in case of challenging therapy response.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120650"},"PeriodicalIF":2.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum SCCA as a biomarker for assessing severity and monitoring treatment response in psoriasis","authors":"Bin Wei ,&nbsp;Bei Cai ,&nbsp;Qian Niu ,&nbsp;Dong Wu ,&nbsp;Limei Luo","doi":"10.1016/j.cca.2025.120644","DOIUrl":"10.1016/j.cca.2025.120644","url":null,"abstract":"<div><h3>Background</h3><div>While clinical examination remains the diagnostic cornerstone for psoriasis, there is a relative lack of objective, quantitative biomarkers to complement clinical assessment for tracking disease severity and monitoring therapeutic response. We evaluated serum SCCA's utility in identifying psoriasis and assessing its severity across demographic (gender, age) and clinical (comorbidity) subgroups, and its association with therapeutic responses.</div></div><div><h3>Methods</h3><div>A total of 181 adult (≥18 years old) patients with newly diagnosed psoriasis were included in the disease group; 385 patients with other skin-related diseases and 658 healthy adults were included as controls. Patients diagnosed with tumors or renal failure were excluded. Serum SCCA was determined using Roche Cobas e 801 analyzer (Roche, Basel, Switzerland). Dynamic analysis was performed to evaluate the significance of serum SCCA in monitoring psoriasis treatment response.</div></div><div><h3>Results</h3><div>Serum SCCA levels in psoriasis patients were mainly affected by gender and concomitant diseases. Notably, SCCA demonstrated high diagnostic accuracy (AUC: 0.89–0.90) in patients with comorbidities, with sex-specific cutoffs. The cutoff value of serum SCCA for identifying severe psoriasis was 2.64 ng/mL with an AUC greater than 0.9 and an NPV over 95 %. Serum SCCA levels were significantly correlated with the psoriasis area and severity index (PASI) and body surface area (BSA) both before and after treatment. The median decrease rate of serum SCCA was close to 50 % at &gt;5 days post-treatment and 60 % at &gt;10 days post-treatment.</div></div><div><h3>Conclusions</h3><div>Serum SCCA shows promise as a reliable, complementary biomarker for the severity assessment and treatment monitoring of psoriasis. Its application for identification purposes should be stratified by sex and comorbidities.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120644"},"PeriodicalIF":2.9,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of monoclonal alpha heavy chains in the absence of other monoclonal proteins in a patient with a history of IgG-κ MGUS","authors":"Morgan W. Mann ,&nbsp;Priscilla S.W. Yeung ,&nbsp;Ruben Y. Luo ,&nbsp;Kara L. Lynch ,&nbsp;Alan H.B. Wu ,&nbsp;Hannah J. Lusk","doi":"10.1016/j.cca.2025.120636","DOIUrl":"10.1016/j.cca.2025.120636","url":null,"abstract":"","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120636"},"PeriodicalIF":2.9,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}